2016 - Health Care for Women Over 40

Menopause Management 2016: New Data, New Medications, New Approaches (Rx = .5 hr.)

Apr 13, 2016 12:30pm ‐ Apr 13, 2016 1:30pm

Expiration Date: May 2, 2019


Credits: None available.

Standard: $18.00

Description

Learning Objectives:

  • To reevaluate hormonal therapy in view of followup data from the Women's Health Initiative, and subsequent studies such as the KEEPS and ELITE hormone trials
  • To discuss newer hormonal data, and its impact on the risk/benefit ratios, for menopause management (for example, transdermal estrogens, alternative progestins, and bazedoxifene)
  • To discuss non estrogen therapies for both vasomotor symptoms and vulvovaginal atrophy (genitourinary syndrome of menopause)

Speaker(s):

Disclosures

  • Mary Minkin, MD:

    Disclosure:

    Pfizer
    Novo Nordisk
    Shionogi
    Vertical Pharmaceuticals
    Enzymatic (Nature's Way)
    Noven pharmaceuticals

    Relationship:

    Consultant
    Consultant
    Consultant
    Consultant
    Consultant
    Consultant

Credits

  • 0.50 - Pharmacology
  • 1.50 - Physician
  • 1.50 - RN / NP (All RNs/Nurses except CA RNs)
  • 1.50 - CA RN/CA BRN

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
* - Indicates answer is required.
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content